Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1192

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

Journal Articles

The Use of Monocyte Subset Repartitioning By Flow Cytometry for Diagnosis of Chronic Myelomonocytic Leukemia

Aarya Murali, MBBS (Hons), Donna Cross, Peter Mollee, FRACP,MBBS,MSc,FRCPA

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-140966

Published: 2020

Journal Articles

Burden of Cardiovascular Events and Bleeding Is High in Myelodysplastic Syndromes

Rakchha Chhetri, MBBS, Oisin Friel, MBBS, Monika M Kutyna, MSc, Kathleen Pao Lynn Cheok, MBBS, Li Yan A Wee, BSc (Hons), Hossam Amin, Rebecca Thompson, B Pharm, Deepak Singhal, MBBS,MDFRACP,FRCPA, Kirsty M Sharplin, MBBS, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-143319

Published: 2020

Journal Articles

Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma

Portia Smallbone, MBBS, Stephanie Clugston, MBBS (Hons), Rebecca De Kraa, BSc, Duncan Purtill, MBBS,FRCPA,FRACP, Matthew Wright, MBBS, FRCPA, FRACP, Michael F. Leahy, FRACP,FRCPath,FRCP, M Hasib Sidiqi, MBBS

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-141783

Published: 2020

Journal Articles

Differences in Clinical Presentation and Outcomes between Metropolitan and Rural Myeloma Patients

Stephanie Clugston, MBBS (Hons), Portia Smallbone, MBBS, Duncan Purtill, MBBS,FRCPA,FRACP, Dustin Hall, MBBS,FRCPA,FRACP, Rebecca De Kraa, BSc, Matthew Wright, MBBS, FRCPA, FRACP, Michael F. Leahy, FRACP,FRCPath,FRCP, M Hasib Sidiqi, MBBS

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141784

Published: 2020

Journal Articles

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Kim Huynh, BBiomedSc (Hons), PhD, Naomi Aoki, MSc, BSc, Kihyun Kim, MD PhD, Wee Joo Chng, MD PhD, Gin Gin Gan, MBBS, MRCP, FRCP, Chang-Ki Min, MD PhD, Je-Jung Lee, MD PhD, Yeow Tee Goh, MBBS, Cameron Wellard, Zoe McQuilten, MBBS, PhD, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136896

Published: 2020

Journal Articles

Bortezomib Induction and Consolidation in Patients with Multiple Myeloma Who Received Frontline Autologous Stem Cell Transplant

Sarah Ai Ting Tan, Steven Shih, MBChB, Scarlett Olasope, MBChB, Sharon R. Jackson, FRACP, FRCPA, Sarah Poplar, MBChB,FRCPath,FRPATH,PGCert,MRCP,ClinEd, Henry Chan, MBChB, FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-140077

Published: 2020

Journal Articles

Weekly Cyclophosphamide, Subcutaneous Bortezomib and Dexamethathasone (CyBorD) for Initial Treatment of Transplant Eligible Patients with Multiple Myeloma: Experience of Two Transplant Centres

Georgia J McCaughan, MBBS, Anvita Verma, MBBS, Silvia Ling, MBBS, PhD, Orly Lavee, MBBS FRACP FRCPA, John Moore, MB.BS, MD FRACP, FRCPA, Adam Bryant, MBBS (Hon) PhDFRACP FRCPA

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-139269

Published: 2020

Journal Articles

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-136574

Published: 2020

Journal Articles

A Shared Electronic Health Record in a Rural Setting Maintains Hematological Cancer Services Remotely during the COVID-19 Pandemic

Helen Cashman, MBBS, Eleni Mayson, FRACP, FRCPA, MBBS, MPhil, David Kliman, MBBS, Sue Vachalec, Jennifer Bell, BN, Sam Milliken, MBBS, FRACP, FRCPA, John Moore, MB.BS, MD FRACP, FRCPA, Orly Lavee, MBBS FRACP FRCPA, Barbara Withers, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 5.

https://doi.org/10.1182/blood-2020-142209

Published: 2020

Journal Articles

The Utility of Leucocyte Cell Population Data and Scattergram in Rapid Identification of Acute Promyelocytic Leukemia

Shruti Mishra, MBBS, MD PDF Hematology, Kishore Kumar, MDMBBS,DM, Ashutosh Panigrahi, MBBS, MD DM, Prabodh Das, MBBS, MD FRCPA, Somanath Padhi, MBBS MD, Gaurav Chhabra, MBBS, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-142498

Published: 2020

Journal Articles

Totality of Scientific Evidence in the Development of ABP 798, a Biosimilar to Rituximab

Dietger Niederwieser, MD PhD, Caroline Hamm, MD, Patrick Cobb, MD, Theingi Thway, PhD, Cecily Forsyth, FRACP, FRCPA, MBBS, Alessandra Tucci, MD, Vincent Delwail, Roman Hajek, MD PhD, Vladimir Hanes, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-142723

Published: 2020

Journal Articles

A Prospective Haploidentical Peripheral Blood Stem Cell Transplant Study Using a Pre-Defined Conditioning Regimen Intensity Based on Age and the Hematopoietic Cell Transplantation Comorbidity Index- Anzhit 1: Encouraging Preliminary Survival Outcomes at One Year Follow up

John Moore, MB.BS, MD FRACP, FRCPA, John Kwan, MBBS,FRACP,FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Ashish Bajel, FRACP, David Ritchie, MB ChB, PhD FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Steven Tran, BEng MBiomedE, Donna Aarons, B.Pharm, Nada Hamad, MB.BS, FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-142131

Published: 2020

Journal Articles

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

Piers Blombery, MBBS, Ella R Thompson, PhD BSc, Xiangting Chen, PhD, Tamia Nguyen, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, John F. Seymour, Constantine S. Tam, MBBS, MD, Michael A Dengler, PhD, David C.S. Huang, MBBS MRCP PhD, Andrew Wei, MBBS,PhD, Andrew W Roberts, MBBS

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-137775

Published: 2020

Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134446

Published: 2020

Journal Articles

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-134460

Published: 2020

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-134611

Published: 2020

Journal Articles

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Natasha S Anstee, PhD, Giovanna Pomilio, Mark Levis, MD PhD, Sarah MacRaild, Michael Murray, PhD DSc, Tristan Rawling, PhD, Glen A Kennedy, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Anthony Schwarer, MBBS, MD FRACP, FRCPA, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, James D'Rozario, MBBS, FRACP, FRCPA, Paula Marlton, MBBS FRACP FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Adam Ivey, BSc, MSc, PhD, Doen Ming Ong, MBBS, Andrew W Roberts, MBBS, Andrew H Wei, MBBS, PhD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-141711

Published: 2020

Journal Articles

The Natural History of NPM1 MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML)

Ing Soo Tiong, MBBS,FRACP,FRCPA, Richard Dillon, MA, PhD MRCP, FRCPath, Adam Ivey, BSc, MSc, PhD, Chung Hoow Kok, BSc, PhD, James Anton Kuzich, MBBS, Nisha Thiagarajah, MBBS, Ashish Bajel, FRACP, Nicola Potter, PhD, Matthew Smith, MBBS, Claire Hemmaway, Abin Thomas, Amanda Gilkes, Nigel H. Russell, MD, Andrew H. Wei

Blood (2020) 136 (Supplement 1): 25–27.

https://doi.org/10.1182/blood-2020-140296

Published: 2020

Journal Articles

Therapy-Related Myeloid Neoplasm Has a Distinct Pro-Inflammatory Bone Marrow Microenvironment and Delayed DNA Damage Repair

Monika M Kutyna, MSc, Li Yan A Wee, BSc (Hons), Sharon Paton, BSc, Dimitrios Cakouros, PhD, Agnieszka Arthur, PhD, Rakchha Chhetri, MBBS, Andreas W Schreiber, PhD, Chung Hoow Kok, PhD BSc, Deepak Singhal, MBBS,MDFRACP,FRCPA, Daniel Thomas, MD PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, David Campbell, PhD B.M.B.S., F.R.A.C.S., F.A.Oth.A, Stan Gronthos, PhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137277

Published: 2020

NARROW

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

The Use of Monocyte Subset Repartitioning By Flow Cytometry for Diagnosis of Chronic Myelomonocytic Leukemia

Burden of Cardiovascular Events and Bleeding Is High in Myelodysplastic Syndromes

Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma

Differences in Clinical Presentation and Outcomes between Metropolitan and Rural Myeloma Patients

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Bortezomib Induction and Consolidation in Patients with Multiple Myeloma Who Received Frontline Autologous Stem Cell Transplant

Weekly Cyclophosphamide, Subcutaneous Bortezomib and Dexamethathasone (CyBorD) for Initial Treatment of Transplant Eligible Patients with Multiple Myeloma: Experience of Two Transplant Centres

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

A Shared Electronic Health Record in a Rural Setting Maintains Hematological Cancer Services Remotely during the COVID-19 Pandemic

The Utility of Leucocyte Cell Population Data and Scattergram in Rapid Identification of Acute Promyelocytic Leukemia

Totality of Scientific Evidence in the Development of ABP 798, a Biosimilar to Rituximab

A Prospective Haploidentical Peripheral Blood Stem Cell Transplant Study Using a Pre-Defined Conditioning Regimen Intensity Based on Age and the Hematopoietic Cell Transplantation Comorbidity Index- Anzhit 1: Encouraging Preliminary Survival Outcomes at One Year Follow up

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

The Natural History of NPM1 MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML)

Therapy-Related Myeloid Neoplasm Has a Distinct Pro-Inflammatory Bone Marrow Microenvironment and Delayed DNA Damage Repair

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only